The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
Among patients with Parkinson disease or parkinsonism undergoing a 30-day multidisciplinary intensive rehabilitation treatment (MIRT), consumption of a twice-daily whey protein-based nutritional supplement enriched with leucine and vitamin D preserved muscle mass and improved lower extremity function.
While AZD0530 is reasonably safe and well tolerated in participants with mild Alzheimer disease (AD), it has no significant effect on cerebral metabolic decline nor on clinical or biomarker measures in AD.
Engaging in regular physical activity and taking active measures to reduce vascular risk may have a synergistic effect in delaying the progression of Alzheimer disease.
According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.
